The implementation of health technology assessment principles in public decisions concerning orphan drugs (original) (raw)
Richter T, Nestler-Parr S, Babela RM, Khan Z et al (2015) Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. Value Health 18:906–9 1 4 ArticlePubMed Google Scholar
EMA, Annual report on the use of the special contribution for orphan medicinal products (2017)
Schey C, Milanova T, Hutchings A (2011) Estimating the budget impact of orphan medicines in Europe: 2010-2020. Orphanet J Rare Dis 6:62 ArticlePubMedPubMed Central Google Scholar
Danzon PM (2018 Mar) Affordability challenges to value-based pricing: mass diseases, orphan diseases, and cures. Value Health 21(3):252–257 ArticlePubMed Google Scholar
Paulden M, Stafinski T, Menon D, McCabe C (2015) Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework. PharmacoEconomics 33:255–269 ArticlePubMed Google Scholar
Drummond M, Towse A (2014) Orphan drugs policies: a suitable case for treatment. Eur J Health Econ 15:335–340 ArticlePubMed Google Scholar
Iskrov G, Stefanov R (2014) Post-marketing access to orphan drugs: a critical analysis of health technology assessment and reimbursement decision-making considerations. Orphan Drugs: Res Rev 4:1–9 Google Scholar
McCormick J, Berescu D, Tadros N (2018) Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand. Orphanet Journal of Rare Diseases 13:27 ArticlePubMedPubMed Central Google Scholar
Hughes-Wilson W, Palma A, Schuurman A, Simoens S (2012) Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis 7:74 ArticlePubMedPubMed Central Google Scholar
Michel M, Toumi M (2012) Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res 12:23–29 ArticlePubMed Google Scholar
Kesselheim AS, Myers JA, Avorn J (2011) Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 305:2320–2326 ArticleCASPubMed Google Scholar
Joppi R, Bertele’ V, Garattini S. orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 2013;69:1009–1024 ArticlePubMed Google Scholar
Dunoyer M (2011) Accelerating access to treatments for rare diseases. Nature 10:475–476 CAS Google Scholar
Regulation (EC) No. 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. Off J Eur Communities 2000;L18:1–5
Clarke JT (2006) Is the current approach to reviewing new drugs condemning the victims of rare diseases to death? A call for a national orphan drug review policy. Can Med Assoc J 174:189–190 Article Google Scholar
Winquist E, Bell CM, Clarke JTR, Evans G, Martin J, Sabharwal M, Gadhok A, Stevenson H, Coyle D (2012) An evaluation framework for funding drugs for rare diseases. Value Health 15:982–986 ArticlePubMed Google Scholar
Wild C, Hintringer K, Nachtnebel A (2011) Orphan drugs in oncology. Pharm Policy Law 13:223–232 Google Scholar
Owen A, Spinks J, Meehan A, Robb T, Hardy M, Kwasha D, Wlodarczyk J, Reid C (2008) A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian pharmaceutical benefits scheme: the Bosentan patient registry. J Med Econ 11:235–243 ArticlePubMed Google Scholar
Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S (2010) Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ 13:295–301 ArticlePubMed Google Scholar
Claxton K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, Sculpher MJ (2008) Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 336:251–254 ArticlePubMedPubMed Central Google Scholar
Hutchings A, Ethgen O, Schmitt C, Rollet P (2012) Defining elements of value for rare disease treatments. Value Health 15(4):A31 Article Google Scholar
McCabe C, Stafinski T, Menon D (2010) Is it time to revisit orphan drug policies? BMJ. 341:c4777 ArticlePubMed Google Scholar
Mentzakis E, Stefanowska P, Hurley J (2011) A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study. Health Econ Policy Law 6:405–433 ArticlePubMed Google Scholar
Moberly T (2005) Rationing and access to orphan drugs. Pharm J 275:569–570 Google Scholar
Pinxten W, Denier Y, Dooms M, Cassiman J, Dierickx K (2012) A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European orphan drug regulation. J Med Ethics 38:148–153 ArticlePubMed Google Scholar
Prevot J, Watters D (2011) HTA’s and access to rare diseases therapies: the view from the PID community. Pharm Policy Law 11:177–181 Google Scholar
Sullivan SD (2008) The promise of specialty pharmaceuticals: are they worth the price? J Manag Care Pharm 14:S3–S6 PubMed Google Scholar
Laupacis A (2009) Evidence and values: requirements for public reimbursement of drugs for rare diseases: a case study in oncology. Can J Clin Pharmacol 16:e282–e284 Google Scholar
Mycka J., Dellamano R., Lobb W. et al., Orphan drugs assessment in germany: a comparison with other international HTA agencies, Volume 18, Issue 7, 2015: A550-A551
Kawalec P, Sagan A, Pilc A (2016) The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe. Orphanet Journal of Rare Diseases 11:122 ArticlePubMedPubMed Central Google Scholar
Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS (2010) Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67. Br Med J 341:c4715 Article Google Scholar
Largent EA, Pearson SD (2012) Which orphans will find a home? The rule of rescue in resource allocation for rare diseases. Hast Cent Rep 42:27–34 Article Google Scholar
Barrett P, Alagely A, Topol E (2012) Cystic fibrosis in an era of genomically guided therapy. Hum Mol Genet 21:R66–R71 ArticleCASPubMed Google Scholar
Garattini S (2012) Time to revisit the orphan drug law. Eur J Clin Pharmacol 68:113 ArticlePubMed Google Scholar
Gupta S (2012) Rare diseases : Canada’s “research orphans”. Open Med 6:23–27 Google Scholar
Kanavos P, Nicod E (2012) What is wrong with orphan drug policies? Suggestions for ways forward. Value Health 15:1182–1184 ArticlePubMed Google Scholar
Owen A, Spinks J, Meehan A, Robb T, Hardy M, Kwasha D, Wlodarczyk J, Reid C (2008) A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian pharmaceutical benefits scheme: the Bosentan patient registry. J Med Econ 11:235–243 ArticlePubMed Google Scholar
Stafinski T, Menon D, McCabe C, Philippon DJ (2011) To fund or not to fund: development of a decision-making framework for the coverage of new health technologies. Pharmacoeconomics 29:771–780 ArticlePubMed Google Scholar
Hutchings A, Schey C, Dutton R, Achana F, Antonov K (2014) Estimating the budget impact of orphan drugs in Sweden and France 2013–2020. Orphanet J Rare Dis 9:22 ArticlePubMedPubMed Central Google Scholar
Torrent-Farnell J, Comellas M, Poveda JL, Abaitua I, Gutiérrez-Solana LG, Pérez-López J, Cruz J, Urcelay J, Lizán L (2018 Mar) The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: a Delphi consensus. Health Policy 15
Menon D, Stafinski T, Dunn A, Short H (2015) Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity? Patient 8:29–39 ArticlePubMed Google Scholar
Gliklich R, Leavy M (2011) Patients registries and rare disease. Appl Clin Trials 20(3)
Douglas CMW, Wilcox E, Burgess M, Lynd LD (2015) Why orphan drug coverage reimbursement decision-making needs patient and public involvement. Health Policy 119(5):588–596 ArticlePubMed Google Scholar